Retatrutide: Triple Agonist Weight Loss Guide

Every weight loss peptide before retatrutide activated one or two receptors. Retatrutide activates three. GLP-1, GIP, and glucagon. That third pathway changes what's possible with an injectable peptide, and the Phase II data reflects it.

Why three receptors matter

GLP-1 suppresses appetite. You've seen this with semaglutide, tirzepatide. It works. Your brain gets satiety signals, your stomach empties slower, you eat less.

GIP improves how your body handles fat. Lipid metabolism gets more efficient, insulin sensitivity improves. Tirzepatide already proved this dual approach works better than GLP-1 alone.

Glucagon is the new piece. Glucagon receptor activation does two things neither GLP-1 nor GIP can do: it increases resting energy expenditure (your body burns more calories just existing) and it drives fat oxidation in the liver specifically. In practical terms, you're not just eating less. Your body is actively spending more energy and breaking down liver fat.

Phase II results

Jastreboff et al., NEJM, 2023. 338 participants. 48 weeks. Multiple dose arms.

The highest dose group hit up to 24% body weight loss in 48 weeks.

To put that in context: tirzepatide's SURMOUNT-1 showed 22.5% at 72 weeks. Retatrutide got to 24% in 48 weeks. Faster, deeper, shorter trial. The glucagon component appears to be adding real metabolic horsepower.

Liver fat also decreased significantly. This was expected given glucagon's known hepatic effects, but seeing it confirmed in trial data is meaningful for people with fatty liver concerns.

Phase III trials are running now. Results expected 2025-2026. These will confirm (or not) whether the Phase II numbers hold up in thousands of participants over longer durations.

Dosing

Similar titration approach to tirzepatide: start low, increase monthly. The Phase II trial used escalating doses over the first 12 weeks, then maintenance. Exact protocols may shift as Phase III data comes in, but the principle is the same. Your gut needs time to adjust to GLP-1 activation, and rushing it causes unnecessary GI distress.

[[Retatrutide|11]] comes in 10mg, 30mg, and 60mg vials. For reconstitution with bacteriostatic water and subcutaneous injection.

[[Retatrutide Pen|38]] is pre-filled in 30mg and 60mg. No reconstitution needed. Dial, inject, done.

Side effects

The GLP-1/GIP-related side effects are familiar: nausea, diarrhea, vomiting during dose escalation. These track closely with what tirzepatide and semaglutide users experience. Transient, manageable with proper titration.

The glucagon-specific angle: some participants saw a modest heart rate increase (5-10 bpm). And glucagon naturally raises blood glucose, though in retatrutide this effect is counterbalanced by GLP-1/GIP activity. Net glucose control was still positive in the trial. These effects are still being fully characterized in Phase III.

No serious safety signals emerged in Phase II. But the dataset is smaller than what we have for tirzepatide, so the long-term picture is still forming.

Retatrutide vs tirzepatide

Tirzepatide has more data. Full Phase III program completed, thousands of participants, well-characterized safety. If evidence depth is your priority, tirzepatide is the safer bet.

Retatrutide has the more aggressive mechanism. The glucagon component adds calorie burning and liver fat targeting that no dual agonist matches. If you want the most powerful metabolic tool currently available and you're comfortable with Phase II evidence, retatrutide is where the frontier is.

Some people do tirzepatide first, stabilize, then transition to retatrutide. Others start directly with retatrutide. Both approaches have a logic behind them.

Need help deciding? Reach out to us and we'll walk through the options based on your situation.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.